<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">AAPS PharmSci</journal-id><journal-id journal-id-type="pmc-domain-id">989</journal-id><journal-id journal-id-type="pmc-domain">pharmsci</journal-id><journal-title-group><journal-title xml:lang="en">AAPS PharmSci</journal-title></journal-title-group><issn pub-type="epub">1522-1059</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC2751528</article-id><article-id pub-id-type="pmcid-ver">PMC2751528.1</article-id><article-id pub-id-type="pmcaid">2751528</article-id><article-id pub-id-type="pmcaiid">2751528</article-id><article-id pub-id-type="pmid">12866946</article-id><article-id pub-id-type="doi">10.1208/ps050221</article-id><article-id pub-id-type="publisher-id">52116</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Atenolol quantification in human plasma by high-performance liquid chromatography: Application to bioequivalence study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>de Abreu</surname><given-names initials="LRP">Luis Renato Pires</given-names></name><address><phone>+55 19 38627110</phone><fax>+55 19 38627110</fax><email>lrpabreu@uol.com.br</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>de Castro</surname><given-names initials="SAC">Silvana Aparecida Calafatti</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pedrazzoli</surname><given-names initials="J">Jos&#233;</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label>Department of Pharmacology, Faculty of Medical Sciences-UNICAMP, Campinas, S&#227;o Paulo Brazil </aff><aff id="Aff3"><label>3</label>Integrated Unit of Pharmacology and Gastroenterology-S&#227;o Francisco, University Medical School, Bragan&#231;a Paulista, S&#227;o Paulo Brazil </aff><aff id="Aff2"><label>2</label>288 Simao Ferreira Alves St, CEP: 13801-525, PO Box 63, Mogi Mirim, S&#227;o Paulo Brazil </aff></contrib-group><pub-date pub-type="collection"><month>6</month><year>2003</year></pub-date><pub-date pub-type="epub"><day>16</day><month>6</month><year>2003</year></pub-date><volume>5</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">181905</issue-id><fpage>116</fpage><lpage>122</lpage><history><date date-type="received"><day>7</day><month>8</month><year>2002</year></date><date date-type="accepted"><day>18</day><month>4</month><year>2003</year></date></history><pub-history><event event-type="pmc-release"><date><day>16</day><month>06</month><year>2003</year></date></event><event event-type="pmc-live"><date><day>14</day><month>10</month><year>2009</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-03-17 02:25:37.093"><day>17</day><month>03</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; American Association of Pharmaceutical Scientists 2003</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12248_2008_Article_52116.pdf"/><abstract xml:lang="en"><p>An accurate, precise, and sensitive high-performance liquid chromatography (HPLC) assay was developed for the determination of atenolol in human plasma samples to compare the bioavailability of 2 atenolol tablet (50 mg) formulations in 24 volunteers of both sexes. The study had an open, randomized, 2-period crossover design with a 1-week washout period. Plasma samples were obtained over a 24-hour interval. Atenolol concentrations were analyzed by combined reversed phase liquid chromatography and fluorescence detection (&#955;<sub>EX</sub> = 258 nm, &#955;<sub>EM</sub> = 300 nm). From the atenolol plasma concentration versus time curves, the following pharmacokinetic parameters were obtained: AUC<sub>0&#8211;24h</sub>, AUC<sub>0&#8211;&#8734;</sub>, and C<sub>max</sub>. The geometric mean of test/reference 50-mg tablets individual percent ratio was 102.2% for AUC<sub>0&#8211;24h</sub>, and 101.6% for C<sub>max</sub>. The 90% confidence intervals (CI) were 100.2% to 105.4% and 100.9% to 103.5%, respectively. Since the 90% CI for both C<sub>max</sub> and AUC<sub>0&#8211;24h</sub> were within the 80% to 125% interval proposed by the Food and Drug Administration, it was concluded that atenolol (50-mg tablets) test formulation was bioequivalent to the reference formulation, with regard to both the rate and extent of absorption.</p></abstract><kwd-group><title>Keywords</title><kwd>atenolol</kwd><kwd>bioequivalence</kwd><kwd>HPLC</kwd><kwd>plasma</kwd><kwd>determination</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; American Association of Pharmaceutical Scientists 2003</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>